Current approaches to the viral gene therapy of PD are aimed at replacement of enzyme activity, e.g., tyrosine hydroxylase (TH), which converts tyrosine to L-DOPA, or aromatic amino acid decarboxylase (AAAD), which converts L-DOPA to dopamine (273). The gene discussed is TH; the disease is Parkinson disease.